Matthew Strickland, MD, on Locally Advanced Gastric/GEJ Cancer: Tislelizumab Plus Chemoradiotherapy

January 20, 2026 By The ASCO Post Staff

Matthew Strickland, MD, of Massachusetts General Hospital, reviews results from the phase IIb TERRIFIC trial, which compared the efficacy and safety of the PD-1 inhibitor tislelizumab plus chemoradiotherapy vs chemoradiotherapy or chemotherapy alone in the neoadjuvant treatment of patients with gastric or gastroesophageal junction adenocarcinoma (Abstract 286). 

Related Content